| Trial ID: | L6620 |
| Source ID: | NCT00659711
|
| Associated Drug: |
Januvia (Sitagliptin) 100 Mg
|
| Title: |
The Effect of Januvia (Sitagliptin) on Oxidative Stress in Obese Type 2 Diabetic Subjects
|
| Acronym: |
1928
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00659711/results
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Januvia (Sitagliptin) 100 mg|DRUG: Placebo
|
| Outcome Measures: |
Primary: Change in Reactive Oxygen Species (ROS) Generation by MNC, Protein and mRNA Expression of p47phox Subunit of NADPH Oxidase, in MNC's of Obese Type 2 Diabetic Patients, 12 weeks | Secondary: Change in Oxidative Stress From Baseline to 12 Weeks, To investigate that therapy with sitagliptin orally daily (100 mg) for 12 weeks decreases oxidized lipids (9-hydroxyoctadecadienoicacid (9-HODE) and 13-HODE) in plasma and F2-isoprostane in urine of obese type 2 diabetic patients Outcome measures given are calculated from the baseline - 12 weeks., value at 12 weeks minus value at baseline
|
| Sponsor/Collaborators: |
Sponsor: University at Buffalo | Collaborators: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
22
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT
|
| Start Date: |
2008-03
|
| Completion Date: |
2013-12
|
| Results First Posted: |
2022-07-21
|
| Last Update Posted: |
2022-07-21
|
| Locations: |
115 Flint Road, Buffalo, New York, 14221, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00659711
|
